Latest Breaking News On - Jonas hannestad - Page 1 : comparemela.com

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease

BETHESDA, Md., April 24, 2024 Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule.

Gain Therapeutics Announces Positive Results from the

BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology.

Gain Therapeutics (GANX) Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying - Alzamend Neuro (NASDAQ:ALZN), Anitra (AMEX:AZTR)

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

BETHESDA, Md., April 01, 2024 Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small molecule therapies,.